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INTRODUCTION
Green tea, a world wide consuming beverage, is known to
have the beneficial effects on the cardiovascular system. In
fact, the intake of green tea in human is proposed to be asso-
ciated with a lower incidence of coronary artery disease (1) and
myocardial infarction (2). In addition, there is evidence that
the consumption of green tea reduces mortality due to cardio-
vascular disease in a large population prospective study (3).
Furthermore, polyphenol (-)-epigallocatechin gallate (EGCG),
the most prominent catechin of green tea, appears to atten-
uate myocardial ischemia/reperfusion (I/R) injury in animal
models (4, 5). However, there is scanty information available
about the molecular mechanisms involved in the EGCG-in-
duced cardioprotection so far. 
Meanwhile, the intracellular calcium ([Ca2+]i) overloading
has been implicated as a primary event in cell injury and necro-
sis in myocardial I/R injury (6). Opening of adenosine triphos-
phate-sensitive potassium (KATP) channels prevents the [Ca2+]i
overload induced by myocardial I/R injury (7). Recent stud-
ies have suggested that mitochondrial KATP (mKATP) channels
are responsible for the marked cardioprotective effect of myocar-
dial ischemic preconditioning and pre-ischemic drug treat-
ment to reduce infarct size (8, 9). Furthermore, there is accu-
mulating evidence that the cardioprotective effects of KATP
channel openers are associated with mKATP activation (10). 
In this regard, it’s reasonable to hypothesize that the activa-
tion of mKATP channels may participate in the cardioprotec-
tive effect by EGCG. Therefore, the purpose of this study was
to determine the involvement of mKATP channels in EGCG-
induced pharmacological preconditioning in isolated rat hearts.
MATERIALS AND METHODS
The experimental procedures and protocols used in this study
were reviewed and approved by our institutional animal care
and use committee of Keimyung Universiry Dongsan Med-
ical Center.
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Polyphenol (-)-Epigallocatechin Gallate during Ischemia Limits Infarct
Size Via Mitochondrial KATP Channel Activation in Isolated Rat Hearts
Polyphenol (-)-epigallocatechin gallate (EGCG), the most abundant catechin of green
tea, appears to attenuate myocardial ischemia/reperfusion injury. We investigated
the involvement of ATP-sensitive potassium (KATP) channels in EGCG-induced car-
dioprotection. Isolated rat hearts were subjected to 30 min of regional ischemia and
2 hr of reperfusion. EGCG was perfused for 40 min, from 10 min before to the end
of index ischemia. A nonselective KATP channel blocker glibenclamide (GLI) and a
selective mitochondrial KATP (mKATP) channel blocker 5-hydroxydecanoate (HD) were
perfused in EGCG-treated hearts. There were no differences in coronary flow and
cardiodynamics including heart rate, left ventricular developed pressure, rate-pres-
sure product, +dP/dtmax, and -dP/dtmin throughout the experiments among groups.
EGCG-treatment significantly reduced myocardial infarction (14.5±2.5% in EGCG
1 mM and 4.0±1.7% in EGCG 10 mM, P<0.001 vs. control 27.2±1.4%). This anti-
infarct effect was totally abrogated by 10 mM GLI (24.6±1.5%, P<0.001 vs. EGCG).
Similarly, 100 mM HD also aborted the anti-infarct effect of EGCG (24.1±1.2%, P<
0.001 vs. EGCG ). These data support a role for the KATP channels in EGCG-induced
cardioprotection. The mKATP channels play a crucial role in the cardioprotection by
EGCG. 
Key Words : Epigallocatechin Gallate; KATP Channels; Myocardial Infarction; Myocardial Ischemia; Myocar-
dial Reperfusion Injury
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Chemicals and antibodies
Pentobarbital sodium (Entobar
�) was purchased from Han-
lim Pharmacy (Yongin, Korea). EGCG and a selective blocker
of mKATP channels (5-hydroxydecanoate, HD) were purchas-
ed from Sigma-Aldrich Chemical (St. Louis, MO, USA). A
nonselective KATP channel blocker glibenclamide (GLI) was
obtained from Tocris Bioscience (Ellisville, MO, USA). 2,3,5-
Triphenyltetrazolium chloride (TTC) was also obtained from
Sigma-Aldrich Chemical. Fluorescent polymer microspheres
were purchased from Duke Scientific Corp. (Palo Alto, CA,
USA). Other chemicals were obtained from Sigma-Aldrich
Chemical. 
Langendorff isolated heart perfusion preparation
Male Wistar rats, weighing 280-330 g obtained from Korea
Takonic (Seongnam, Korea), were used throughout the exper-
iments. They received 100 mg/kg of pentobarbital sodium
and 300 IU of heparin intraperitoneally. Hearts were isolat-
ed and perfused with modified Krebs-Henseleit solution con-
taining (in mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2,
24.8 NaHCO3, 1.2 KH2PO4, and 10 glucose, as described
previously (11). In order to induce regional ischemia, the proxi-
mal portion of left coronary artery (LCA) was first localized
between the left atrial appendage and the right ventricular
outflow tract. This was then followed by the passage of a 6-
0 polypropylene suture around the major trunk of the LCA
or its prominent branches. The ends of the thread were passed
through a small piece of PE50 tube to form a snare. All hearts
were then allowed to stabilize for at least 30 min. Ischemia
was induced by pulling the snare and then fixing it by clamp-
ing the tubing with a small hemostat and was confirmed by
regional cyanosis, a substantial decrease in left ventricular
developed pressure (LVDP), or a fall in coronary flow. Reper-
fusion was initiated by releasing the snare. Hearts experienc-
ing ventricular fibrillation (VF) usually revert spontaneous-
ly to sinus rhythm. VF lasting more than 45 sec was treated
with finger flick cardioversion until a perfusing rhythm was
obtained. No pharmacological agents were used for defibril-
lation.
Assessment of cardiac function 
The functional recovery by EGCG was compared with con-
trol hearts. To do this, an air-bubble free, Krebs-Henseleit
buffer-filled elastic balloon made of polyethylene plastic con-
nected to a pressure transducer with tubing was inserted into
the left ventricle (LV) through the left atrial appendage. The
balloon was coupled to a graded threaded micro-syringe and
balloon volume was adjusted to give a left ventricular end-
diastolic pressure (LVEDP) of 5-10 mmHg at the beginning
of the experiment. LVDP was calculated as the difference bet-
ween the left ventricular systolic pressure (LVSP) and LVEDP.
Coronary flow was measured by a timed collection of the per-
fusate dripping from the right heart into a graduated cylin-
der. Cardiodynamic data, including heart rate, LVSP, LVEDP,
and the maximum and minimum of first derivative of left
ventricular pressure (+dP/dtmax and -dP/dtmin) were continu-
ously recorded with the MP150 pressure transducer (BioPac
Systems, Santa Barbara, CA, USA), and analyzed using anal-
ysis software (Acqknowledge, version 3.9.0.). The rate-pres-
sure product (RPP) was calculated as LVDP×heart rate (12). 
Experimental protocol 
All hearts were subjected to 30 min of regional ischemia
and 2 hr of reperfusion and each group consisted of at least
7 hearts. Isolated hearts were assigned randomly to one of the
following groups; 1) Control, no other intervention either
before or after LCA occlusion; 2) EGCG1, 1 mM of EGCG;
and 3) EGCG10, 10 mM of EGCG (Fig. 1). Following sub-
group hearts were used to determine the involvement of KATP
channels in EGCG induced cardioprotetion using a nonse-
lective KATP channel blocker GLI and a selective mKATP chan-
nel blocker HD; 4) EGCG+GLI EGCG with 10 mM GLI;
5) EGCG+HD; EGCG with 100 mM HD; 6) GLI alone; and
7) HD alone. Compounds were infused for 40 min, from 10
min before to the end of index ischemia. Drugs were diluted
with Krebs-Henseleit solution to the required final concen-
trations, as described above, on the day of each experiment.
The concentrations of KATP channel blockers used in this study
were based on previous studies for isolated working rat hearts
(13, 14). 
Exclusion criteria 
We decided prospectively that any hearts with a heart rate
less than 250 beats/min, or coronary flow more than 18 mL/
min or less than 8 mL/min at the end of stabilization would
be excluded from the study. Hearts failing to develop LVSP
of more than 80 mmHg when the LVEDP was kept 5-10
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Fig. 1. Experimental protocols. For measurement of contractile
function and infarct size, isolated rat hearts were exposed to 30
min ischemia followed by 2 hr reperfusion. Drugs were perfused
from 10 min before and to the end of index ischemia. 
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mmHg and hearts exhibiting arrhythmia during stabiliza-
tion period also discarded.
Determination of area at risk and infarct size 
At the end of each experiment (2 hr after reperfusion), the
area at risk (AAR) and area at necrosis (AN) were measured
as described in our previous study (11). In brief, LCA perfu-
sion circuit was reoccluded, and diluted fluorescent polymer
microspheres with 2-9 mm in diameter were infused to demar-
cate the AAR. The hearts were weighed, frozen at -20℃for
1-3 hr, and cut into 2 mm thick transverse slices using a rat
heart slice matrix (Zivic Instruments, Pittsburgh, PA, USA).
The slices were incubated in 1% TTC in sodium phosphate
buffer (pH 7.4) at 37℃for 20 min. The slices were immers-
ed in 10% formalin to enhance the contrast between viable
(stained) and necrotic (unstained) tissue. LV was removed from
the remaining tissue and then the LV slices were compressed
to a uniform 2 mm thickness by placing them (basal side) bet-
ween two glass plates separated by a 2 mm space. The AAR
of myocardium was identified by illuminating the slices with
U.V. light as the tissue without fluorescence. The AN (un-
stained by TTC) and AAR (no fluorescence) zone regions were
traced on a clear acetate transparent sheet and quantified with
the Image Tool (UTHSCSA Image Tool, version 3.0). The
areas were converted into volumes by multiplying the areas
by slice thickness. The volume of AN was expressed as a per-
centage of the AAR volume. All measurements were per-
formed in a blinded fashion.
Statistical analysis 
Data are expressed as means±SEM. Data analysis was per-
formed with a personal computer statistical software pack-
age (SPSS for Windows, Release 12.0; SPSS Inc, Chicago, IL,
USA). One-way analysis of variance with Tukey’s HSD post
hoc test was used to determine whether any significant differ-
ences existed in cardiodynamic parameters and infarct mea-
surements between groups. Chi square analysis was used to
test differences in the incidence of VF. Differences were con-
sidered to be statistically significant when P values were less
than 0.05.
RESULTS 
A total of 53 rat hearts were used for this experiment. All
hearts presented in results were perfused within 30-40 sec
after excision. Three hearts were excluded from data analysis
for the following reasons: coronary flow >18 mL/min (n=1),
LVDP <80 mmHg (n=1), or heart rate <250 beats/min (n=
1) during the stabilization period. Therefore, we report the
data for 50 successfully completed infarct experiments.
Incidence of ventricular fibrillation 
No heart had VF during ischemia or after 30 min of reper-
fusion. VF occurred during early reperfusion and appeared
either as a transient self-limiting episode or as a persistent
episode which need finger flick cardioversion. VF occurred
in 17 of 50 hearts (3/8 in control. 2/7 in EGCG1, 2/7 in EG-
CG10, 2/7 in EGCG+GLI, 2/7 in GLI, 3/7 in EGCG+HD,
and 3/7 in HD) during early reperfusion. There was no sig-
nificant difference in the incidence of VF among groups. 
Determination of infarct size 
Table 1 presents body weight, heart weight, and LV vol-
ume. There were no significant differences in these parame-
ters among the groups. Table 1 also presents risk volume data
for the groups. Risk volume averaged 0.275 cm3 to 0.320 cm3
and was not statistically different among groups (P>0.05).
The mean AAR for each experimental group ranged from
53.6% to 63.2% for LV volume. There were no significant
differences in the ratio of AAR to LV volume among the groups
and these results indicates that all groups were subjected to
equivalent degrees of regional ischemia. This result means
that the changes in the infarct size observed between various
groups in our experiments were not related to the degree of
ischemic area.
Values are mean±SEM. 
No., number of hearts; LV, left ventricle; AAR, are at risk; EGCG, polyphenol (-)-epigallocatechin gallate; EGCG1, 1 mM EGCG; EGCG10, 10 mM EGCG;
GLI, 10 mM glibenclamide (a nonselective KATP channel blocker); HD, 100 mM 5-hydroxydecanoate (a mitochondrial KATP channel blocker). 
Body weight
(g)
Heart weight
(g)
LV volume
(cm
3)
AAR volume
(cm
3)
AAR/LV
(%)
No. Groups
Control 8 303.1±6.2 1.43±0.05 0.500±0.022 0.289±0.014 58.2±2.9
EGCG1 7 315.0±4.2 1.40±0.04 0.508±0.050 0.285±0.038 55.4±3.0
EGCG10 7 317.9±3.4 1.41±0.05 0.494±0.029 0.294±0.023 59.7±3.9
EGCG+GLI 7 309.3±5.6 1.44±0.03 0.485±0.018 0.287±0.018 60.1±4.9
GLI 7 300.0±4.9 1.41±0.02 0.489±0.020 0.305±0.008 63.2±3.7
EGCG+HD 7 314.3±3.2 1.36±0.05 0.516±0.029 0.320±0.015 62.4±2.3
HD 7 307.1±6.4 1.35±0.05 0.512±0.038 0.275±0.026 53.6±2.9
Table 1. Morphometrics of the experimental ratsEGCG Reduces Myocardial Ischemic Injury 383
As shown in Fig. 2, infarct volume in the control hearts
was 27.2±1.4% of the AAR zone. The ratio of infarct vol-
ume/ischemic volume (AN/AAR) in our control hearts was
smaller than those reported by others (11, 12), however, this
is in agreement with our recently reported study (13). 
EGCG treatment during ischemic period significantly
reduced myocardial infarction (14.5±2.5% in 1 mM EGCG
and 4.0±1.7% in 10 mM EGCG, P<0.001 vs. control). The
AN/AAR was more markedly attenuated by 10 mM EGCG
than by 1 mM EGCG (P=0.003). To confirm the involvement
of KATP channels in infarct limitation effect by EGCG, we
examined whether a nonselective KATP channel blocker GLI
and a selective mKATP channel blocker HD could limit the
anti-infarct effect by 1 mM EGCG. The infarct limitation effect
by 1 mM of EGCG was totally abrogated by 10 mM GLI (24.6
±1.5%, P<0.001 vs. EGCG). Similarly, 100 mM HD also
aborted the anti-infarct effect of EGCG (24.1±1.2%, P<
0.001 vs. EGCG) (Fig. 3). Treatment of control hearts with
GLI or HD alone had infarct size of 23.7±2.5% and 21.0±
1.0%, respectively, which were not different compared with
the infarct size in the untreated control hearts (P>0.05). 
Cardiac function recovery
The baseline coronary flow and cardiac function parameters
are given in Table 2. There were no significant differences in
coronary flow and hemodynamic indexes concerning heart
rate, LVDP, RPP, +dP/dtmax, and -dP/dtmin at baseline among
the groups. There were no significant differences in coronary
flow and heart rate among groups throughout the experiments
(data not shown). The LVDP, RPP, +dP/dtmax, and -dP/dtmin
after 2 hr of reperfusion in control hearts were 48.0±3.3%,
Fig. 2. Area at necrosis (AN) expressed as a percentage of the AAR
(area at risk) in control hearts and hearts treated with the polyphe-
nol (-)-epigallocatechin gallate (EGCG). Open circles indicate the
infarct sizes from individual hearts. Filled circles in each group indi-
cate the group mean infarct size; mean±SEM. Both concentrations
(1 and 10 mM) of EGCG treatment during ischemic period signifi-
cantly attenuate AN/AAR in isolated rat hearts. EGCG1, 1 mM EGCG;
EGCG10, 10 mM EGCG. 
*P<0.001 vs. control; 
� P<0.05 vs. EGCG1.
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Fig. 3. Area at necrosis (AN) expressed as a percentage of the
AAR (area at risk) by treatment of 10 mM glibenclamide (GLI) and
100 mM 5-hydroxydecanoate (HD) combined with 1 mM polyphe-
nol (-)-epigallocatechin gallate (EGCG) during ischemic period in
isolated rat hearts. Open circles indicate the infarct sizes from indi-
vidual hearts. Filled circles in each group indicate the group mean
infarct size; mean±SEM. Both a nonselective KATP channel blocker
GLI and a mitochondrial KATP channel blocker HD totally blocked
the anti-infarct effect by EGCG. Treatment of control hearts with
GLI or HD alone had no effect on infarct size. 
*P<0.001 vs. control. 
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Values are mean±SEM. 
No., number of hearts; CF, coronary flow; HR, heart rate; LVDP, left ventricular developed pressure; RPP, rate-pressure product; +dP/dtmax, maximum
positive left ventricular pressure derivative; -dP/dtmin, minimum negative left ventricular pressure derivative; EGCG, polyphenol (-)-epigallocatechin gallate;
EGCG1, 1 mM EGCG; EGCG10, 10 mM EGCG; GLI, 10 mM glibenclamide (a nonselective KATP channel blocker); HD, 100 mM 5-hydroxydecanoate (a
mitochondrial KATP channel blocker). 
CF
(mL/min)
HR
(beats/min)
LVDP
(mmHg)
RPP
(mmHg/min/10
3)
+dP/dtmax
(mmHg/sec/10
3)
-dP/dtmin
(mmHg/sec/10
3)
No. Groups
Control 8 12.9±0.2 281.0±8.8 115.9±11.3 34.0±2.9 2.4±0.1 -2.4±0.2
EGCG1 7 13.4±0.6 293.3±5.4 117.5±6.8 34.5±2.1 2.5±0.2 -2.4±0.1
EGCG10 7 13.6±0.6 290.9±7.7 114.7±10.3 33.2±2.7 2.5±0.2 -2.4±0.2
EGCG+GLIb 7 13.1±0.4 303.6±4.5 123.5±2.4 37.5±1.0 2.6±0.1 -2.4±0.1
GLI 7 12.6±0.7 291.6±7.4 116.9±4.7 34.0±1.4 2.7±0.2 -2.5±0.2
EGCG+HD 7 12.4±0.4 282.2±3.5 113.5±5.8 32.1±2.0 2.3±0.2 -2.2±0.2
HD 7 12.3±0.5 295.3±7.8 112.4±10.1 33.2±3.1 2.5±0.2 -2.1±0.1
Table 2. Baseline coronary flow and cardiodynamic data384 D.-K. Song, Y. Jang, J.H. Kim, et al.
46.1±3.6%, 49.1±3.8%, and 46.7±2.4%, respectively,
of the baseline levels. The functional recovery parameters by
EGCG after 2 hr of reperfusion were not different with con-
trol hearts (Fig. 4). 
DISCUSSION 
The treatment of EGCG, a major polyphenolic substance
found in green tea, during ischemia significantly attenuated
the infarct size after 2 hr of reperfusion in our isolated rat hearts.
The current results confirm that EGCG treatment during
ischemia protects against myocardial infarction. The infarct
limitation effect by EGCG was totally abolished by a nons-
elective KATP channel blocker GLI, indicating the involve-
ment of KATP channels in anti-infarct effect by EGCG. We
further tested the hypothesis that the involvement of mKATP
channels on EGCG-induced anti-infarct effect. The infarct
limitation effect by EGCG was totally attenuated by a selec-
tive mKATP channels blocker HD. This result indicates, for
the first time, that EGCG treatment during ischemia medi-
ates mKATP channels, and thereby reduces infarct size in iso-
lated rat hearts. In our isolated rat hearts, 1 mM EGCG treat-
ment during ischemia significantly reduced the infarct vol-
ume (-50%) and the infarct limitation effect was more promi-
nent in 10 mM EGCG treatment (-85%) compared to control
hearts. In a previous study, Townsend et al. (5) firstly report-
ed that 100 mM of EGCG perfusion prior to index ischemia
lessened the extent of infarct size approximately 27% against
the whole heart in the isolated rat hearts. We do not know
the exact reason of the difference in the degree of anti-infarct
effect between our and Townsend group’s results, but the per-
fusion timing of the EGCG and the infarct measurement may
account for it. We perfused EGCG from 10 min before to the
end of index ischemia but they perfused EGCG 30 min before
undergoing myocardial ischemia. Besides we expressed the
infarct volume as a percentage of the AAR volume of the LV
volume, but they measured the infarct size by measuring the
infarct area against the whole heart including right ventricle.
Otherwise, it may be attributable to the fact that high con-
centrations of EGCG (100 mM) directly inhibits sarcolem-
mal KATP (sarcKATP) channels via interacting with lipid mem-
brane (14), thereby lessens its protective effects. It is suggest-
ed that oral ingestion more than 50 cups of green tea is requir-
ed to achieve 10 mM EGCG concentration in the human plas-
ma (15), and oral intake of green tea for 3 cups in fasting state
and 10 cups in feast state can achieve 1 mM EGCG concen-
tration in human plasma (16). In this regard, it is considered
that EGCG concentration more than 10 mM may not be suit-
able to clinical settings to evaluate the efficacy of EGCG in
myocardial ischemic injury. In our preliminary study, appli-
cation to the bath solution of natural green tea extract con-
taining a 1 mM EGCG during ischemic period significantly
attenuated infarct volume of the LV volume (10.3±1.1%,
n=8) compared with untreated myocardial I/R rat hearts (27.4
±2.1%, n=8, P<0.05). This is the reason that we used 1 mM
EGCG for further experiment to investigate the involvement
of KATP channels in the infarct limitation effect induced by
EGCG, although the anti-infarct effect was more prominent
in 10 mM EGCG preconditioned hearts. 
It is well known that [Ca2+]i overload is closely correlated
with myocardial damage and cell death during ischemia (17).
In myocardium, sarcKATP channels were originally postulated
to participate in salvage from irreversible I/R injury, because
their opening would produce an increase in the outward potas-
sium current leading to shortening of action potential dura-
tion, which would in turn reduce the Ca2+influx through volt-
age-dependent Ca2+ channels and increase the time during
which the Na+/Ca2+ exchanger would operate to extrude Ca2+
from the cell (18). We have reported previously that EGCG
can modulate sarcKATP channels via reducing its sensitivity
to ATP, which closes the channel, and to phosphatidylinosi-
tol polyphosphates (PIP), which open the channel (19). The
potency of EGCG to reduce the channel ATP sensitivity is
revealed to be greater in the cardiac-type channels than in the
beta cell-type channels. Therefore, it can be speculated that
reduced ATP sensitivity of cardiac KATP channels by EGCG
may be, at least partially, related with EGCG-mediated car-
dioprotection. However, this hypothesis should be further
determined because the channel PIP sensitivity can also be
reduced by EGCG, resulting in the channel be difficult to
open. 
It is well accepted that ischemia causes increases in intrami-
tochondrial calcium concentrations ([Ca2+]m), resulting in
further calcium-dependent events leading to cell damage (20).
As calcium enters the mitochondria during ischemia, water
follows, leading to mitochondrial matrix swelling and even-
tually mitochondrial rupture and myocyte death. The open-
ing of mKATP channels results in mitochondrial K+ influx,
Fig. 4. Functional recovery after 30 min of index ischemia followed
by 2 hr of reperfusion in isolated rat hearts. EGCG treatment dur-
ing ischemia did not change the functional recovery concerning
LVDP, RPP, +dP/dtmax, and -dP/dtmin after 2 hr of reperfusion. 
LVDP, left ventricular developed pressure; RPP, rate-pressure
product; +dP/dtmax and -dP/dtmin, maximum and minimum of first
derivative of left ventricular pressure derivative. 
F
u
n
c
t
i
o
n
a
l
 
r
e
c
o
v
e
r
y
 
(
%
 
o
f
 
B
a
s
e
l
i
n
e
)
80
60
40
20
0
LVDP RPP +dP/dtmax -dP/dtmin
Control EGCGEGCG Reduces Myocardial Ischemic Injury 385
expansion of the mitochondrial matrix volume, and a reduc-
tion of the inner mitochondrial membrane potential estab-
lished by the proton pump. This change is expected to dec-
rease the driving force for Ca2+ influx, therefore attenuating
[Ca2+]m overload under conditions (such as I/R) in which cyto-
solic calcium is increased (21). Therefore, opening of mKATP
channels has been proposed to play an important role in car-
diac protection such as in ischemic and pharmacological pre-
conditioning (22). The current results, indicating that the
EGCG-induced anti-infarct effect is totally inhibited by HD,
suggest that mKATP channel opening by EGCG during ische-
mia may be directly responsible for cardioprotection. Tissue
salvage by an anti-infarct intervention would lead to an im-
provement in cardiac function. The increase in [Ca2+]i is likely
to explain the depressed ability of I/R hearts to generate con-
tractile force (23, 24). However, reduction in infarct size is not
always associated with an improvement in functional recov-
ery due to the continued stunning or the possibility that the
salvaged tissue is not yet normal (25). In a previous study,
preischemic infusion of EGCG (100 mM) significantly ame-
liorated cardiac function during postischemic phase (5). How-
ever, no significant difference was observed in the treatment
of 1 mM EGCG, which is more reliable concentration in clini-
cal settings, during ischemia compared to control group in
our isolated rat hearts, although there was significant infarct
limitation effect. The interaction between mitochondrial per-
meability transition pores (mPTP) and the mKATP channels
was previously suggested by findings indicating that diazox-
ide (an mKATP channel opener) -induced preconditioning was
inhibited by an mPTP opener atractyloside (26, 27). A role
for mPTP inhibition was also suggested in pharmacological
preconditioning produced by volatile anesthetics desflurane
(28, 29). Therefore, the possibility of the involvement of mPTP
by EGCG treatment should be determined in the future. 
In conclusion, perfusion of EGCG during ischemia signifi-
cantly reduces infarct size after reperfusion and the mKATP
channels play a crucial role in EGCG induced cardioprotec-
tion. 
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